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Apelin receptor (APJ) and bradykinin B2 receptor (B2R) play an important role in 
many physiological processes and share multiple similar characteristics in distribution 
and functions in the cardiovascular system. We first identified the endogenous 
expression of APJ and B2R in human umbilical vein endothelial cells (HUVECs) and 
their co-localization on human embryonic kidney (HEK) 293 cells membrane. A suite 
of bioluminescence and fluorescence resonance energy transfer (BRET and FRET), 
proximity ligation assay (PLA), and co-immunoprecipitation (Co-IP) was exploited to 
demonstrate formation of functional APJ and B2R heterodimer in HUVECs and 
transfected cells. Stimulation with apelin-13 and bradykinin (BK) increased the 
phosphorylation of the endothelial nitric oxide synthase (eNOS) in HUVECs, which 
could be inhibited by the silencing of APJ or B2R, indicating the APJ-B2R dimer is 
critical for eNOS phosphorylation in HUVECs. Furthermore, the increase of NOS and 
extracellular signal regulated kinases1/2 (ERK1/2) phosphorylation mediated by 
APJ/B2R dimer can be inhibited by U0126 and U73122, respectively, suggesting that 
the heterodimer might activate the PLC/ERK1/2/eNOS signaling pathway, and finally 
leading to a significant increase in cell proliferation. Thus, we uncovered for the first 
time the existence of APJ-B2R heterodimer and provided a promising new target in 
cardiovascular therapeutics. 
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GPCR G-protein-coupled receptor 
APJ apelin receptor 
B2R bradykinin B2 receptor 
BK bradykinin 
BRET bioluminescence resonance energy transfer 
FRET fluorescence resonance energy transfer 
PLA proximity ligation assay 
eNOS endothelial nitric oxide synthase 
ERK1/2 extracellular signal regulated kinases 1/2 
DAPI 4′,6-diamidino-2-phenylindole 
PLC phospholipase C 
Co-IP co-immunoprecipitation 











shRNA short hairpin RNA 
VSMC vascular smooth muscle cell 
 
1. Introduction 
G-protein coupled receptors (GPCRs) constitute the largest family of cell surface 
receptors, and are essential components for the initiation of signal transduction from 
the outside to the inside of cells. Because they play crucial roles in the regulation of 
nearly every physiological process, GPCRs represent the targets for about 30% of 
globally marketed drugs [1, 2]. Although GPCRs were initially thought to perfectly 
function as monomeric entities, increasing evidence suggests that they can exist as 
dimers or oligomers which affect ligand binding, receptor traffic and signaling [3]. 
Numerous GPCRs have been shown to dimerize, and APJ or B2R are no exception [4, 
5].  
Apelin, a family of peptides derived from a 77-amino-acid prepropeptide, exert 
their physiological effects through binding to the apelin receptor (also known as APJ) 
[6], a member of the GPCR super-family. Apelin and APJ are widely distributed in the 
heart and vasculature, and play important roles in the physiology and pathophysiology 
of the cardiovascular system [7]. It has been demonstrated that apelin-13 possesses 
stronger activity compared to apelin-17 and apelin-36 [7]. Apelin usually binds to APJ 
and activates downstream Gαi/Gαo signaling, inhibiting cAMP production and 
inducing the phosphorylation of p42/44 ERKs [8]. Besides acting as a monomer, APJ 
heterodimerizes with other GPCR that regulate physiological function, including 
κ-opioid receptor (KOR) [9], angiotensin II type-1 receptor (AT1R) [10], neurotensin 
receptor 1 (NTSR1) [11], orexin receptor type 1 (OX1R) [12] and so on. 
Bradykinin B2 receptor (B2R) and bradykinin B1 receptor (B1R) both belong to 
the family of GPCRs. In general, BK and kallidin bind to B2R which is constitutively 
expressed in a majority of healthy tissues, and particularly in endothelium and 
vascular smooth muscle cell (VSMC), while des-Arg9-BK and des-Arg10-kallidin 
bind to B1R which is expressed under pathological conditions of tissue injury [13, 14]. 
Most of the physiological functions of kinins are mediated by B2R, and the major 
action of the B2R proceeds through Gαq subunit, resulting in PLC-mediated 
intracellular calcium mobilization. On the other hand, BK/B2R system could promote 
cell proliferation and vascular fibrosis through stimulating activation of ERK1/2 
pathway [15, 16]. Likewise, the direct interaction between B2R and other GPCRs has 
been confirmed, causing changes in cell signaling and receptor functions. It has been 
demonstrated that B2R dimerize with TX-prostanoid receptors [5], dopamine D2 
receptor (D2R) [17], AT1R and AT2R [18, 19], P2Y2 ATP receptors [20], as well as 
with KOR [21].  
APJ and B2R share many congenerous characteristics. They are ubiquitously 
expressed in various cells of the cardiovascular system under both normal and 
diseased conditions where they exhibit similar functions in cardiovascular protection. 
For example, both receptors can promote angiogenesis by enhancing the expression of 
eNOS and vascular endothelial growth factor [22, 23]. In addition, Han et al. found 











with human urinary kallidinogenase through enhancing expression of apelin/APJ in 
ERK1/2 dependent way [24]. Finally, APJ and B2R could form functional dimers 
with different GPCRs. However, the likelihood of APJ-B2R heteromerization is not 
reported. 
In this study, bioluminescence/fluorescence resonance energy transfer (BRET and 
FRET) microscopy, the proximity ligation assay (PLA) and co-immunoprecipitation 
(Co-IP) were used to measure the molecular proximity between APJ and B2R in 
HUVECs and transfected HEK293 cells, providing evidence for the quantification of 
receptor heterodimerization. Meanwhile, we examined whether the heterodimer 
changed the signal transduction of monomers, with particular interest in the 
phosphorylation of eNOS and ERK1/2, which play a critical role in the modulation of 
cardiovascular protection [25, 26]. Moreover, we demonstrated the effects of 
APJ-B2R dimers on cell activities. 
 
2. Materials and methods 
2.1. Plasmid constructs 
The pcDNA3.1-APJ and pcDNA3.1-B2R plasmids were obtained from the UMR 
cDNA Resource Center (University of Missouri-Rolla, USA). Cyan fluorescent 
protein (CFP) or mVenus was attached to the C-terminus of APJ and B2R by inserting 
the open reading frame of APJ and B2R into the CFP-N1 or mVenus-N1 vector to 
create APJ-CFP and B2R-Venus. For the APJ-Rluc, the coding sequence of human 
APJ lacking a stop codon was subcloned into pRluc-N1 (BioSignal Packard, Inc., 
Montreal, Canada). To construct pEGFP-APJ, cDNA encoding human APJ was 
cloned into pEGFP-C1 (Clontech, USA). Other constructs presented herein were 
made using standard molecular biology as described previously [21]. All the resulting 
constructs were confirmed by commercial sequencing. 
 
2.2. Cell culture and transfection 
HUVECs and HEK293 cells were cultured in DMEM (GIBCO) with 10% fetal 
bovine serum (FBS) (Sigma-Aldrich) at 37°C in a 5% CO2 humidified incubator. To 
carry out transient transfection experiments, different plasmids were transfected into 
cells using Lipofectamine 2000 reagent according to the manufacturer’s instructions. 
Membrane receptor expression was detected by reverse transcription-polymerase 
chain reaction (RT-PCR). 
 
2.3. Immunostaining and confocal microscopy 
HEK293 cells grown on coverslips were transiently transfected with pEGFP-APJ 
and pcDNA3.1-B2R and fixed after 24 h as previously described [21, 27]. 
Nonspecific binding was blocked by incubation with 3% bovine serum albumin 
prepared in PBS pH7.4 for 1 h at room temperature, and then permeabilized for 30 
min with 0.01% Triton-X-100 in PBS. Cells were washed three times with PBS and 
incubated with an anti-B2R monoclonal antibody (1:200) in PBS at 4°C overnight. 
Cells were washed three times with PBS, followed by incubation with 











Invitrogen) for 1 h at room temperature. After a final wash with PBS, the cells were 
examined by Leica TCS SP8 scanning confocal microscope (Leica Microsystem, 
Germany). 
 
2.4. Enzyme-linked immunosorbent assay(ELISA) 
APJ and B2R expression in HEK293 cells was quantitatively assessed by ELISA 
[28]. The HA-APJ and Myc-B2R plasmids were alone or co-transfected into HEK293 
cells. After 24 hours, HA-APJ, Myc-B2R, or HA-APJ/Myc-B2R cells were 
subcultured in 96-well microplates at a density of 2 × 105 cells per well. Cells were 
fixed with paraformaldehyde (4%) in PBS at room temperature for 30 min, and then 
washed three times with PBS. Next, cells were blocked in PBS containing 3% BSA, 
followed by incubating with primary mouse anti-Myc antibodies or rabbit anti-HA 
antibodies (Cell Signaling Technology) overnight at 4 °C. After washing three times 
with PBS, cells were incubated with goat anti-mouse or goat anti-rabbit horseradish 
peroxidase-conjugated secondary antibody for 1 h at 37 °C. After washing three times, 
the substrate 3,3′,5,5′-tetramethylbenzidine (200 μL) was added and incubated for 30 
min at 37 °C, finally stopped with 50 μL of 0.2M H2SO4. The orange color reaction 
appeared only when the substrate reacted with the peroxidase enzyme conjugated to 
the secondary antibody, and the optical density was measured at 450 nm using an 
iMark Microplate reader (Bio-Rad , USA). 
 
2.5. Bioluminescence resonance energy transfer (BRET) assays 
 HEK293 cells were transiently co-transfected with vectors encoding Rluc fusion or 
Venus fusion proteins. Twenty-four hours after transfection, cells were detached and 
transferred (105 cells/ well) to a 96-well microplate microplate white plates with an 
opaque bottom (Corning 3600, Stockholm, Sweden) in HEPES-buffered phenol 
red-free medium (Invitrogen, Life Technologies) for 24 h. Cells were then washed 
twice and resuspended in D-PBS (PBS containing 0.5 mM MgCl2 and 0.1% (w/v) 
glucose). Coelenterazine H substrate was used at final concentration of 5 μM. 
Analysis was made immediately using a Tristar LB941 plate reader (Berthold 
Technologies, Germany). The BRET ratio is defined as previously described by 
Pfleger et al [29]. The cells co-transfected with KOR-Rluc and mOX2αR-Venus were 
used as a negative control. BRET saturation curves were obtained by transiently 
transfecting constant or increasing amounts of plasmids encoding the Rluc-tagged 
donor constructs and the Venus-tagged constructs, respectively. The total amount of 
plasmid DNA was kept constant by adding empty plasmid. 
 
2.6. Fluorescence resonance energy transfer (FRET) assays 
 To further study the heterodimerization of APJ and B2R, FRET was carried out in 
living cells. The donor plasmid APJ-CFP and the receptor plasmid B2R-mVenus were 
co-transfected into HEK293 cells for FRET assays. HEK293 cells transfected with 
KOR-CFP and mOX2αR-Venus were used as a negative control. FRET signals were 
detected using FLUOstar OPTIMA (BMG Labtech, Offenburg, Germany) and 











detected with two filter settings (CFP: excitation at 436 ± 10 nm and emission at 480 
± 20 nm; mVenus: excitation at 480 ± 20 nm and emission at 535 ± 15 nm; FRET: 
excitation at 436 ± 10 nm and emission at 535 ± 15 nm). The equation: FRETc 
=FRET-(coefficient B × CFP)-(coefficient A × Venus) was used to calculate corrected 
FRET. Here, FRET, CFP and mVenus values correspond to background-corrected 
images obtained from their respective channels. Coefficient B and coefficient A 
correspond to the values obtained for the CFP and Venus bleed-through co-efficient, 
respectively, which were calculated using cells transfected with CFP and Venus 
individually [30, 31]. Normalized FRET ( FRETN) was calculated using the equation: 
FRETN = FRETc / (CFP × Venus). FRETc, CFP and Venus correspond to the 
fluorescence values obtained from single-transfected cells. 
 
2.7. PLA 
To study the APJ-B2R APJ-B2R proximity, the PLA was performed using Duolink 
detection kit as described previously [32, 33]. HEK293 cells co-transfected with APJ 
and B2R were grown on glass slides and fixed with 4% paraformaldehyde for 20 min. 
To detect APJ-B2R heteromers, slides were incubated with goat anti-APJ and rabbit 
anti-B2R antibodies at 4 °C overnight in a humidifying chamber. Slides were then 
washed and incubated with secondary anti-goat/rabbit antibodies conjugated PLA 
probes at 37 °C for 1 h. Slides were washed again and incubated with ligation-ligase 
solution, followed by incubation with amplification-polymerase solution. Slides were 
then mounted with a minimal volume of Duolink II mounting medium containing 
DAPI for 30 min. PLA signals were detected at room temperature under a Leika SP8 
confocal microscope equipped with oil immersion objective (×63). 
 
2.8. Co-immunoprecipitation (Co-IP)  
Cells were lysed in 1% RIPA lysis buffer (Beyotime, Jiangsu, China) containing 
protease inhibitor cocktail (Sigma). Cell lysates containing 2 mg of protein were 
incubated with the anti-APJ (Thermofisher , PA5-80343) or anti-B2R (Huabio, 
ET7106-74) antibody/protein A/G agarose complex overnight at 4℃, after mounting 
on a slowly rotating wheel. The beads were washed three times with with TBST and 
once with 4× SDS-PAGE sample buffer. Equal amounts of proteins were resolved by 
10% SDS–PAGE and subjected to western blotting. Detection of proteins by 
immunoblotting with anti-B2R (Affinity, DF8337) and anti-APJ(Bioss, bs-2430R) 
antibodies was conducted using an ECL system (Beyotime). 
 
2.9. Western blotting 
HUVECs and HEK293 cells were harvested in RIPA lysis buffer and the proteins 
concentration was measured using a bicinchoninic acid (BCA) Analysis Kit (KeyGEN, 
Nanjing, China). Equal aliquots of protein samples were separated on 10% 
SDS-PAGE gels and subsequently electrotransfered to PVDF membranes (Amersham 
Biosciences). The membranes were blocked with 5% lipid-free milk at room 
temperature for 1 h, followed by incubation with a primary antibody against B2R, 











times, the membrane was exposed to a HRP-conjugated secondary antibody (1:5000) 
at room temperature for 1 h and washed three times for 10 min/time with TBST. The 
immunoreactive proteins were visualized by ECL chemiluminescent reagent. 
Anti-GAPDH antibody was used as a loading control. 
To assay eNOS and ERK1/2 activation, HUVECs endogenously expressing APJ 
and B2R were made quiescent by serum starvation for 24 hours prior to treatment 
with apelin-13 or BK. Following treatment, cells were harvested in RIPA lysis buffer. 
Subsequently, 10 μg of cell extracts was separated by 10% SDS-PAGE. Gel transfer 
was performed at 150 mA for ~90 min. Phosphorylation of eNOS and ERK1/2 were 
detected by immunoblotting with an antibody anti-phospho-eNOS (Ser1177(C9C3) 
Rabbit mAb) (Cell Signaling, USA) or anti-phospho-ERK1/2 antibody (Cell 
Signaling Technology) (1:2000). As a loading control, the same membranes were 
re-probed with an anti-total eNOS (eNOS (6H2) Mouse mAb) (Cell Signaling, USA) 
or anti-total ERK1/2 antibody (Cell Signaling Technology) (1:2000). The band 
intensities were measured by densitometric analysis, and the change in eNOS and 
ERK1/2 phosphorylation was calculated as the phospho-eNOS/eNOS and phospho- 
ERK1/2/ERK1/2 ratio, respectively.  
For RNAi experiments, HUVEC cells were transiently transfected with either APJ 
shRNA (Sigma; clone ID: NM_004041.3-828s21c1) or B2R shRNA (Genechem; 
clone ID: NM_000623), and shRNA negative control (CTRL) , according to the 
manufacturer’s instructions using Lipofectamine 2000 reagent as previously described 
[32]. After 48 h, the cells were collected for eNOS assays, with or without incubation 
with apelin-13 or BK for the indicated time periods. For U0126 and U73122 
experiments, HUVECs were pretreated with ERK1/2 inhibitor U0126 (10 μM) for 1 h 
or phospholipase C (PLC) inhibitor U73122 (10 μM,) for 30 min, followed by 
stimulation with apelin-13 or BK (10−7 M) for 10 min. 
 
2.10. Cell cycle analysis 
For determining the cell cycle arrest properties, HUVECs were seeded in 6-well 
plates at a density of 1×105 cells/well. After 24 h, HUVECs were transfected with 
shRNA-APJ or shRNA-B2R plasmids. To confirm that the shRNA for B2R or APJ 
has no off-target effects on APJ or B2R, the APJ inhibitor F13A (1μM, 30 min) or 
B2R inhibitor HOE140 (10 μM, 30 min ) was used prior to their agonists. After 48 h, 
all cells were treated with apelin-13 or BK (10-7 M) for 48 h. Then, cells were 
harvested by centrifugation and were incubated with propidium iodide (PI) using flow 
cytometric kits (EXBIO, Vestec, Czech Republic) according to the manufacturer’s 
recommendations [34]. In brief, the cell plates were dissolved in a mixture of PBS and 
RNase A solution and incubated for 30 min. Then 1 mL of the Tris buffer solution was 
blended with 100 mL of PI solution and added to each cell sample. Ultimately, after 
30 min incubation time in the dark at room temperature, the cell cycle analysis was 
carried out by a flow cytometry cytometer (Becton-Dickinson, USA). 
 
2.11. Statistical analysis 











using GraphPad Prism 8.0. The number of samples (n) in each experiment is provided 
in the figure legends. Statistical analysis was performed using an unpaired Student’s 
t-test or a One Way ANOVA for more than two treatment conditions followed by 
Tukey’s test. Values of P<0.05 were considered as statistically significant. All 
experiments were repeated at least three times, and representative images are shown 
in the figures.  
 
3. Results 
3.1. Co-expression and Co-localization of APJ and B2R in HEK293-APJ/B2R cells 
and HUVECs  
Total proteins of HUVECs were identified for Western blot, which demonstrated 
that there were 43 kDa (APJ) protein band and 45 kDa (B2R) protein band (Figure 
1A), suggesting both the APJ and B2R express in HUVECs. However, neither of the 
receptors was detected in HEK293 cells. To identify the co-localization of APJ and 
B2R in HEK293 cells cotransfected with pcDNA3.1-B2R and N-terminal 
EGFP-tagged APJ, immunofluorescence image analysis was carried out using 
confocal microscopy. APJ and B2R were predominantly expressed at the cell 
membrane (Figure 1B), implying that they may interact. Cell nuclei were visualized 
by DAPI staining. 
To examine cell surface expression of APJ and B2R, ELISA assay was also carried 
out by using anti-HA and anti-Myc antibodies, respectively. Two fusion proteins 
HA-APJ and Myc-B2R that were N-terminally epitope-tagged with HA or Myc tags 
were detected. After co-expression in HEK293 cells, it was found that the cell surface 
expression of HA-APJ or Myc-B2R was not increased in APJ/B2R heterodimer 
(Figure 1C). The result from Figure 1C showed that the expression level of APJ and 
B2R did not change by co-expression. 
 
3.2. APJ physically interacts with B2R 
Using a variety of approaches, we examined if the functional interaction between 
APJ and B2R was the consequence of physical heteromerization between the two 
receptors. First, We carried out BRET experiments that allows the detection of energy 
transfer between one receptor bearing the BRET donor (Renilla luciferase) and the 
second receptor bearing the acceptor (green fluorescent protein) when the two 
receptors are in close proximity (<50Å ) [35]. Under these conditions, we observed a 
highly significant BRET signal in cells coexpressing tagged APJ and B2R (Figure 2A). 
No significant BRET signal was observed in cells coexpressing KOR-Rluc and 
mOX2αR-Venus or co-transfected with Rluc and B2R-Venus, Venus and APJ-Rluc. 
The findings were supported by the demonstration of these complexes in cellular 
models using a BRET saturation assay. A saturable and strong BRET signal was found 
in the HEK293 cells cotransfected with APJ-Rluc and B2R-Venus (Figure 2B). BRET 
signaling demonstrated a hyperbolic function in response to increasing amounts of 
transfected B2R-Venus, reaching saturation at the highest concentrations obtained, 
whereas the negative controls with coexpressing KOR-Rluc and mOX2αR-Venus 











was further supported by the observation that pcDNA3.1 vector unlike wild APJ and 
B2R failed to compete with the formation of the APJ-B2R complex, as seen from a 
nonreduced BRET ratio in competition experiments (Figure 2C). Accordingly, 
receptor heteromers were also visualized as red spots by using PLA in cells 
expressing APJ and B2R but not in cells expressing KOR and mOX2αR (Figure 2D). 
FRET was performed to further explore the interaction between APJ and B2R. 
HEK293 cells were transfected with APJ-CFP (a), B2R-Venus (b), KOR-CFP and 
mOX2αR-Venus (c), or APJ-CFP and B2R-Venus (d) (Figure 3A). In images of FRET, 
the site of interaction will be marked as yellow or red. Moreover, a more intense color 
means a stronger interaction. There was no significant FRET in all single-transfected 
cells (Figure 3, A and B). As a negative control, no significant FRET was visualized in 
cells cotransfected with KOR-CFP and mOX2αR-Venus. However, a notable FRET 
signal was clearly detected in HEK293 cells co-transfected with APJ-CFP and 
B2R-Venus. To verify the above results, Co-IP was used to investigate the possibility 
of APJ-B2R interactions in HUVECs. From Figure 3C, we can find that in the 
HUVECs coexpressing both APJ and B2R, APJ (or B2R) could be found in 
sedimentation precipitated with anti-B2R (or anti-APJ ) antibody (Figure 3C). Thus, 
Co-IP assay indicated that APJ and B2R constitute a complex.  
 
3.3. Apelin-13 or BK increases eNOS phosphorylation in HUVECs via APJ-B2R 
dimers 
To determine whether APJ/B2R dimer formation affected the cellular signal 
transduction, time- and dose-dependent eNOS phosphorylation were investigated in 
HUVECs. The ability of APJ-B2R dimers to stimulate phosphorylation of eNOS was 
assessed by treating cells with apelin-13 or BK (10-7 M) for 0-60 min. As shown in 
Figure 3, apelin-13 significantly enhanced activation of eNOS, with maximal increase 
at 10 min and a return to near basal conditions after 60 min (Figure 4, A and C). In 
next experiments, stimulation of HUVECs with apelin-13 or BK led to a 
dose-dependent increase in P1177-eNOS levels (Figure 4, B and D). The results 
showed that apelin-13 and BK induced the time- and dose-dependent variations of 
eNOS phosphorylation via APJ-B2R heterodimers. 
 
3.4. Knockdown of APJ or B2R in HUVECs affects APJ/B2R-mediated eNOS 
phosphorylation 
To critically evaluate the role of APJ/B2R heterodimer-mediated signalling, we 
transfected shRNA-APJ or shRNA-B2R into HUVECs endogenously expressing both 
APJ and B2R receptors to observe the physiological relevance and the effects of the 
two receptors on eNOS phosphorylation. Western blot analyses showed that APJ and 
B2R were expressed in HUVECs, but treatment with shRNA-APJ or shRNA- B2R 
significantly decreased the expression of APJ or B2R protein (Figure 5, A and B). To 
investigate the effects of shRNA for APJ or B2R on B2R or APJ expression, RNAi 
experiments were further conducted. As shown in Figure 5A and B, shRNA for APJ 
reduced the B2R expression and vice versa. 











eNOS phosphorylation compared to HUVECs transfected with negative control 
shRNA-APJ (P<0.01, Figure 5, C and E). Likewise, B2R depletion also reduced the 
apelin-13 or BK induced eNOS phosphorylation by 50-60% (Figure 5, D and F). 
These results suggests that the response of eNOS phosphorylation to apelin-13 or 
BK is mediated by the APJ-B2R heteromers. 
 
3.5. APJ-B2R dimer induces eNOS phosphorylation via ERK1/2 signaling  
Our previous study demonstrated that APJ/NTSR1 dimer induced phosphorylation 
of ERK1/2 and cell proliferation via Gaq-mediated mechanism [11]. To examine 
whether APJ-B2R dimer affects the ERK1/2 phosphorylation, dose-dependent effects 
of Apelin-13 and BK on ERK1/2 activation were then determined. It can be seen from 
the Figure 6A and C that the ERK1/2 phosphorylation increased gradually with the 
increase of the concentration of apelin-13 and BK, reaching the maximum at 10-7 M. 
To determine whether the phosphorylation of ERK1/2 was mediated by APJ-B2R 
dimers, the shRNA-APJ or shRNA-B2R was applied. As shown in Figure 6B and D-E, 
the results indicate that the phosphorylation of ERK1/2 reduced after APJ or B2R 
silenced compared to the control groups. As ERK1/2 could phosphorylate eNOS 
protein, we tend to ask whether the two factors interact in HUVECs under APJ-B2R 
dimers condition. Then HUVECs were pretreated with ERK1/2 inhibitor U0126 to 
inhibit ERK1/2 activation for 1 h prior to apelin-13 or BK. As shown in Figure 6F and 
G, p-ERK1/2 level was elevated by apelin-13 or BK action, and U0126 treatment 
greatly reduced this augmentation. Interestingly, the p-eNOS levels also reduced in 
the presence of U0126, which was consistent with the change trend of p-ERK1/2. 
To examine whether eNOS phosphorylation is PLC-dependent in HUVECs, the 
cells were treated with the PLC inhibitor U73122 prior to apelin-13 or BK. The level 
of eNOS phosphorylation in HUVECs was significantly lower with U73122 treatment 
than without U73122 treatment (Figure 6, H and I). Furthermore, after the 
shRNA-APJ or shRNA-B2R was applied, the phosphorylation of eNOS significantly 
reduced compared to the control groups, showing that APJ and B2R are used as a 
complex to trigger PLC signal pathway. Collectively, these results strongly suggested 
that APJ-B2R dimer not only enhanced eNOS phosphorylation but also activated this 
protein via PLC-ERK1/2 pathway. 
 
3.6. APJ-B2R dimers promote the cell cycle at the S phase 
We investigated whether APJ-B2R dimers influences the arrest of the cell cycle in 
HUVECs. For this purpose, HUVECs were transfected with shRNA-APJ or 
shRNA-B2R plasmids, then were treated with apelin-13 or BK for 48 h and subjected 
to flow cytometry. As Figure 7 shows, in the HUVECs cell line, compared with those 
in the RNA interference group, the percentages of S phase cells increased from 16.12% 
to 22.92% (P<0.01, Figure 7A and B), 15.82% to 22.99% (P<0.01, Figure 7D and E), 
respectively. To confirm that the shRNA for B2R or APJ has no off-target effects on 
APJ or B2R, the APJ inhibitor F13A (10-7 M) or B2R inhibitor HOE140 (10 μM ) was 
used prior to their agonists. As shown in Figure 7, when the APJ inhibitor F13A was 











cells significantly decreased. The similar results was found in B2R inhibitor group. 
These results indicate that APJ-B2R dimers significantly increase the HUVECs cell 
cycle at the S phase (Figure 7E). In other words, APJ-B2R dimers promotes cell 
proliferation after treated with apelin-13 or BK. 
 
4. Discussion 
The APJ and B2R are increasingly becoming an important subject for investigation 
in the cardiovascular system [37-39]. Although it has been described that both 
receptors are distributed in the same system and have many overlapped functions and 
signal pathways, the direct interaction between both receptors is not known. 
In the present study, using a variety of methods such as RET assays, PLA and 
CO-IP, we demonstrate physical and functional interactions between APJ and B2R in 
recombinant as well as in HUVECs. At first, we confirmed the co-expression of APJ 
and B2R in HUVEC by RT-PCR and western blotting. Confocal microscopy images 
and ELISA showed the localization of APJ and B2R in plasma cell membrane. The 
identification of APJ-B2R heteromers was first carried out via biophysical technique 
BRET and FRET in co-transfected HEK293 cells. The results showed that APJ 
constitutively heteromerizes with B2R, but not with the unrelated receptor mOX2αR. 
The specificity was further supported by BRET saturation and competitive analyses, 
as previously described [40], so the interaction caused by molecular crowding is 
excluded. Several studies have reported that ligands binding may affect heterodimer 
formation [41, 42], whereas apelin-13 or BK treatment did not modulate the BRET 
ratio (data not shown).  
In the FRET experiments, We labeled two receptors with CFP and mVenus, 
respectively, because CFP/Venus is the most popular pair of fluorescent proteins, 
along with its improved variants [43]. As a newly emerging technology, the PLA, 
which can detect nearby proteins within forty nanometers [44], has been used to 
identify heteromerization of μ-opioid receptors (MOR) and α2A-adrenoceptors in the 
nucleus tractus solitarii neurons [45], and heteromerization of chemokine receptor 
type 4 with α1A/B-adrenoceptors [46]. Complementary to the results of the PLA 
technique, data from the Co-IP experiments showed that bands corresponding to each 
of B2R and APJ could be detected within the eluted protein complexes, following the 
immunoprecipitation of HUVECs protein lysates with anti-APJ or anti-B2R. This 
implies that APJ and B2R could be closely associated in HUVECs. Thus, findings 
from the RET, PLA and co-IP experiments support the likelihood of APJ-B2R 
heteromerization. 
Increasing studies have shown that GPCR heteromer can induced biochemical 
properties that are different from its individual receptors, such as ligand-binding 
properties, receptor-mediated G-protein activity, trafficking properties, and signal 
transduction [47]. For example, the CB1-D2 receptor dimers can switch CB1 from 
Gαi to Gαs coupling even in the absence of D2 agonist [48]. Both D1 and D2 
receptors modulate the effector adenylyl cyclase, whereas D1-D2 receptor heteromer 











KOR and B2R can also heterodimerize to switch KOR from Gαi to Gαs coupling, 
leading to increase of cAMP levels [33]. B2R could constitutively interact with 
angiotensin Mas (1-7) receptor, resulting in unique signaling properties [50]. APJ 
inhibits the AT1R signalling via allosteric trans-inhibition [10] . This kind of 
interaction plays an important role in many biological processes. Thomas et al [51]. 
found that PAR4-P2Y12 heterodimer activate Akt signaling, indicating that 
β-arrestins play a critical role in integrin activation in vascular inflammation. Cesario 
et al. [52] demonstrated that low-dose CsA when combined with Cereport (selective 
agonist of B2R) protected nigral neurons and striatal fibers from 6-hydroxydopamine 
neurotoxicity, but not when given alone. 
Thus, we focused on the determination of the functional characteristics of APJ-B2R 
receptor heteromers expressed in HUVECs. The previous reports have revealed that 
both APJ or B2R can signal through the eNOS pathways [53, 54]. For instance, BK 
promots activation of eNOS, leading to an increase of NO and subsequently leading to 
the regulation of vasomotor responses [55]. As a vasodilator and signaling molecule, 
NO plays an important physiological function including the regulation of the vascular 
tone, inhibition of platelet aggregation, the regulation of cell immune and so on. In 
addition, NO formation increased cGMP levels, reducing aortic hypertrophy and 
blood pressure elevation [56]. The disorders of NO biological function will causing 
the loss of heart protection factors, leading to the development of cardiovascular 
disease. Likewise, apelin-13 stimulates angiogenesis by promoting the eNOS 
phosphorylation in myocardial microvascular endothelial cells [57].  
Therefore, we explored the implication of heteromer formation on these pathways. 
Finding in Figure 5 showed that APJ-B2R dimer increased the phosphorylation of 
eNOS in a dose- and time-dependent manner after treatment with apelin-13 or BK. 
However, when APJ or B2R were interfered by their respective specific shRNA, the 
levels of eNOS phosphorylation at Ser1177 significantly decreased after treated with 
apelin-13 or BK, indicating that the APJ-B2R heteromers might mediate the eNOS 
phosphorylation as a signaling units. In addition, both of them can reduce the 
expression of each other and affect the formation of dimer, which further indicates 
that they function as a complex. Similar phenomena occurs in other GPCR dimers. In 
the case of CB1R-DOR heterodimers, binding of CB1 receptor agonist or antagonist 
increased or inhibited the binding and consequently signaling of DOR agonist [58]. 
For instance, A2AR promoted the recruitment of β-arrestin2 to the D2R while reduced 
Gαi-mediated signal of the D2R in A2AR-D2R [59]. The 5-HT2AR-D2R heteromer did 
not result in altered calcium signaling, whereas the NTS1R agonist NT (8-13) 
decreases the Gαq-mediated Ca2+ signal in the NTS1R-D2R dimer [60], suggesting 
that the allosteric interactions can occur at GPCR heteromers to form different 
conformations, resulting in different binding properties [61]. 
As we reviewed previously, many factors including GPCR induced phosphorylation 
of ERK1/2 through activating Gq-PI3K-Raf or other signaling pathways [62]. Various 
research reported that both apelin-13/APJ and BK/B2R system could promote VSMC 
proliferation and angiogenesis by up-regulating activation of ERK1/2 signal pathway 











phosphorylation of ERK1/2. Interestingly, inhibiting ERK1/2 by its inhibitor U0126 
significantly attenuated the activation of eNOS, suggesting that APJ-B2R dimer 
triggered the ERK1/2-eNOS pathway. Moreover, activation of eNOS mediated by 
ERK1/2 has been reported by other studies [65], where ERK1/2 increased eNOS 
phosphorylation in ischemic limb muscle in vivo.  
In a monomeric state, B2R can be coupled with multiple G-proteins Gαq, Gαs, and 
Gαi, but mainly Gαq, whereas APJ mainly activate Gαi and partially Gαq. Several 
receptor pairs have been reported that cross-talk between Gαi- and Gαq-coupled 
receptors typically leads to a potentiation of Gαq coupling [66, 67]. Thus, we propose 
that activation of ERK1/2-eNOS mediated by APJ-B2R dimer is primarily regulated 
by activation of the Gαq subunit. Here, the surprising ability of U73122 to block 
eNOS phosphorylation indicates that APJ-B2R heteromer triggered the PLC pathway, 
which was usually induced by Gαq proteins. This is in agreement with our previous 
study of the formation between APJ and NTSR1 heterodimer, where Gαq is 
preferentially activated. Many studies exploring the role of GPCR heteromers in 
vascular remodeling and cell growth [68, 69]. The roles of APJ-B2R interaction in 
HUVECs proliferation (Figure 7) further suggests that the receptor dimer could 
represent a novel drug target for cardiovascular disease.  
Taken together, we demonstrated for the first time the proximity and interaction 
between APJ and B2R in HUVECs and co-transfected HEK293 cells that was 
constitutive with possible implications on downstream PLC-ERK1/2-eNOS signaling, 
promoting cell proliferation. However, more insights are required for revealing the 
molecular mechanism of the heterodimer to provide new potential drug targets for 
cardiovascular disease. It is very important to search receptor-heteromer selective 
compounds or reagents (monovalent antibodies or membrane permeant peptides) for 
the treatment of a variety of physiologic disorders. Preclinical data suggest that A2A –
D2R receptor antagonist SCH-442416 could be useful in the treatment of drug 
addiction [70]. Thus, the further study is to reveal the critical interface and amino 
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Figure 1. Co-expression and co-localization of APJ and B2R in HUVECs and 
HEK293 cells. (A) APJ (left, 43KD) and B2R (right, 45KD) expression in HUVECs 
and HEK293 cells were detected by western blotting. (B) Confocal microscopy 
analysis of the co-localization of APJ and B2R was performed in HEK293 cells after 
transient co-transfected with pEGFP-APJ (green) and pcDNA3.1-B2R. 
pcDNA3.1-B2R was immunostained with AlexaFluor 647 (red). Co-localization is 
showed in merged images. Nuclei appears in blue. Immunofluorescence was 
measured with a Leica SP8 confocal microscope. (C) Determination of cell surface 
expression of APJ and B2R. HA-tagged APJ and Myc-tagged B2R were transfected 
singly or together into HEK293 cells. ELISA was conducted with intact cells using 











determinations. NS, non-significant. 
 
Figure 2. APJ-B2R dimerization assessed by BRET and PLA. (A) Heterodimerization 
of APJ and B2R was measured in the four indicated conditions by BRET. Twenty-four 
hours after transfection, the fluorescence and luminescence of each sample were 
measured prior to every experiment to confirm equal expression of Rluc while 
monitoring the increase in Venus expression. BRET ratios were analyzed and 
expressed as the means ± SEM of four experiments. ⁎⁎⁎P<0.001 vs. other three 
groups. (B) BRET saturation assay. HEK293 cells were transfected with Rluc 
construct and increasing amounts of the Venus construct. BRET, expressed as mBU, is 
given as a function of 1000 ratio of fluorescence of the acceptor (Venus) and 
Luciferase activity of the donor (Rluc). Data are mean±SEM，n=3. (C) BRET 
competition experiment for the APJ-B2R receptor complexes. A fixed ratio (1:1) of 
expression levels of the APJ-Rluc and B2R-Venus plasmids was used in the presence 
of increasing concentrations of wild-type receptors and pcDNA3.1+ vector. Data were 
expressed as means ± SEM of six experiments. ⁎⁎P< 0.01, ⁎⁎⁎P < 0.001 vs. 
pcDNA3.1+ group. (D) Confocal microscopy images (superimposed sections) from 
PLA experiments performed in HEK-293 cells transfected with APJ cDNA and B2R 
cDNA (left) or KOR cDNA and mOX2αR cDNA (right). Heteromeric complexes 
appearaed red spots and nuclei was stained with DAPI (blue). 
 
Figure 3. Assessment of dimerization of APJ and B2R using FRET and co-IP assays. 
(A) FRET imaging of constitutive APJ-B2R heteromeric interactions in living cells. 
HEK293 cells were transiently transfected (co-expressed or individually expressed) 
with the following plasmids: (a) APJ-CFP, (b) B2R-Venus, (c) KOR-CFP and 
mOX2αR-Venus, and (d) APJ-CFP and B2R-Venus. Left-hand panels, CFP; center 
panels, Venus; right-hand panels, corrected FRET. (B) Calculated normalized FRET 
values were assessed and shown as described in the Materials and Methods. ⁎⁎⁎P 
<0.001 vs. other groups. Data are means ± SEM of at least three independent 
experiments. (C) APJ-B2R interactions in HUVEC as revealed by Co-IP. HUVECs 
lysates were immunoprecipitated with anti-APJ followed by immunoblotting with 
anti-B2R (upper panels) antibodies, or immunoprecipitated with anti-B2R followed 
by immunoblotting with anti-APJ (lower panels), successively. 
 
Figure 4. Activity of APJ/B2R-mediated p1177-eNOS phosphorylation in HUVECs 
after treated with apelin-13 or BK. (A) Time-dependent p1177-eNOS phosphorylation. 
HUVECs were treated with apelin-13 (10-7 M) or BK (10-7 M) for 0 min, 5 min, 10 
min, 15 min, 30 min and 60 min. (B) Dose-dependent p1177-eNOS phosphorylation. 
HUVECs were treated with apelin-13 (10-11-10-7 M) or BK (10-11-10-7 M) for 10 min. 
The time-dependent and dose-dependent effects of the treatments were quantified 
(C-D). All the data represent the mean ± SEM of three measurements from three 
independent experiments. *P< 0.05, ** P <0.01 compared to basal. 
 











phosphorylation. HUVECs were transfected with shRNA-APJ or shRNA-B2R, and 
the control shRNA (CTL) as the negative control. Representative APJ or B2R western 
blots from un-transfected, control shRNA-, or specific shRNA-transfected HUVEC 
are shown (A and B, upper lands). GADPH was used as the loading control. (C-F) 
HUVECs were transfected with shRNA-APJ, shRNA-B2R or control shRNA as 
previously described, and cells were treated or untreated with apelin-13 (10-7 M) or 
BK (10-7 M) for 10 min. Phosphor1177-eNOS (p-eNOS) expression were detected by 
Western blot, eNOS was used as the loading control. *P< 0.05, **P< 0.01 vs. control 
shRNA group. 
 
Figure 6. ERK1/2-eNOS signaling induced by APJ-B2R dimers. (A) Dose-dependent 
ERK1/2 phosphorylation. HUVECs were treated with apelin-13 (10-11-10-7 M) or BK 
(10-11-10-7 M) for 10 min. The dose-dependent effects of the treatments were 
quantified (C). (B) The effects of shRNA-APJ or shRNA-B2R on the phosphorylation 
of ERK1/2. HUVECs transfected with shRNA-APJ or shRNA-B2R were treated with 
apelin-13 (10-7 M) or BK (10-7 M) for 10 min. (D-E) *P<0.05 in comparison with 
shRNA-B2R group, **P<0.01 in comparison with shRNA-APJ group. (F-G) 
HUVECs were pretreated with ERK1/2 inhibitor U0126 (10 μM for 1 h) followed 
stimulated with apelin-13 or BK (10−7 M) for 10 min. (H-I) HUVECs were 
transfected with or without receptors shRNA, and then pretreated with PLC inhibitor 
U73122 (10 μM for 30 min) followed treated with apelin-13 or BK (10-7 M) for 10 
min. All results are mean ± SEM of at least three independent experiments. *P<0.05, 
**P<0.01 for pairwise comparisons.  
 
Fig.7 HUVECs cell cycle induced by apelin-13 or BK, as determined by flow 
cytometry. The cell cycle distribution of HUVECs was determined after treatment 
with apelin-13 (A), apelin plus shRNA-B2R (B), apelin plus HOE140 (C) or BK (D), 
BK plus shRNA-APJ (E), BK plus F13A (F). (G) Flow cytometry analysis showed 
that shRNA-APJ, shRNA-B2R, HOE140 or F13A inhibited cell cycle proliferation by 
reducing S phase arrest. Data are presented as the mean±SEM from three independent 
experiments, *P<0.05, **P<0.01. 
 
Highlights 
 APJ and B2R form heterodimers that function as a novel pharmacological entity. 
 APJ/B2R heteromers mediate the PLC-ERK1/2-eNOS signaling pathway. 
 Apelin-13 enhances proliferation of HUVECs. 
 We reveal the molecular mechanism underlying cardiovascular protection mediated by 
APJ/B2R heterodimers. 
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